XYou may have noticed, we have just launched our new website. We will be adding more features over the upcoming weeks that you will like, so there may be a few hiccups along the way. If this is your first time visiting since our relaunch, please reset your password so you can still access our journals and CME activities that we have been providing for over 80 years. If you have any questions or comments please contact us at webadmin@psychiatrist.com.
XYou may have noticed, we have just launched our new website. We will be adding more features over the upcoming weeks that you will like, so there may be a few hiccups along the way. If this is your first time visiting since our relaunch, please reset your password so you can still access our journals and CME activities that we have been providing for over 80 years. If you have any questions or comments please contact us at webadmin@psychiatrist.com.
Since 2013, when DSM-5 was published, a third of the patients previously diagnosed with bipolar disorder no longer qualify as having the disorder. So what does this say about those who did meet the stricter DSM-5 criteria?
Treatment of severely depressed children at risk for bipolar disorder is challenging. Read about an 11-year-old girl with depression, suicidal ideation, and family history of bipolar disorder whose symptoms remitted after lithium monotherapy.
Treatment of severely depressed children at risk for bipolar disorder is challenging. Read about an 11-year-old girl with depression, suicidal ideation, and family history of bipolar disorder whose symptoms remitted after lithium monotherapy.
Family history plays an important role in bipolar disorder, with apparent polygenic interactions. This case report highlights the importance of monitoring family members of patients with bipolar disorder as a preventive strategy.
Women who take mood stabilizers have a greater risk of placenta-mediated pregnancy complications. But are the mood stabilizers themselves responsible for this higher risk? This study explores that question.
Given the similarity in clinical presentation between major depressive disorder (MDD) and the depressive episodes of bipolar disorder (BP), misdiagnoses occur too often. Read this Academic Highlights to learn to make an accurate differential diagnosis between MDD and BP while recognizing complexities related to not only psychiatric and medical comorbidities but also the evolving presentation of symptoms as the disorders progress.
Clozapine is essential for the management of treatment-refractory schizophrenia, but its use is often limited by side effects. Read this report of a man who developed dysarthria and delirium after receiving subtherapeutic doses of clozapine.
The prevalence of pediatric bipolar disorder is an ongoing topic of debate, and the body of research has grown in recent years. Read this article to learn about current prevalence and the factors that may affect prevalence.
What are some risk factors for (and protective factors against) sexually transmitted infections among adolescents and young adults with bipolar disorder?
Children whose bipolar disorder is inadequately treated often grow into adults who are unable to manage their illness. Read this new Brief Report to discover the most effective treatment strategies to help patients and families learn to control and cope with their bipolar disorder, particularly episodes of depression, as they advance towards adulthood.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”